Answers are grounded in this paper and cite their sources.
Background: TSR-042, a humanized monoclonal antibody, targets programmed death (PD)–1 effectively blocking interaction with its ligands PD-L1 and PD-L2. TSR-042 is being evaluated in patients with advanced solid tumors in the ongoing phase 1 GARNET trial (NCT02715284).1 We present safety and efficacy data from the microsatellite instability-high (MSI-H) endometrial cancer (EC) cohort, pharmacokinetics (PK) and receptor occupancy (RO) at the recommended phase 2 dose (RP2D), as well as biomarker analyses.
No takes yet. Share an insight, caveat, or question.
Oaknin et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: